The prescription of isotretinoin to women: Is every precaution taken?

British Journal of Dermatology

Volumn 138, Issue 3, 1998, Pages 450-455

  Holmes, S C ^a   Bankowska, U ^b   Mackie, R M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; ISOTRETINOIN; ORAL CONTRACEPTIVE AGENT;

ABORTION; ACNE; ARTICLE; CLINICAL PRACTICE; DRUG CONTRAINDICATION; FETUS MALFORMATION; HUMAN; INFORMED CONSENT; MEDICAL RECORD; PATIENT COUNSELING; PREGNANCY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; TERATOGENICITY; UNITED KINGDOM;

ABORTION, THERAPEUTIC; ACNE VULGARIS; CONTRACEPTION; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; ISOTRETINOIN; KERATOLYTIC AGENTS; PATIENT EDUCATION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY TESTS; QUESTIONNAIRES; SCOTLAND; TERATOGENS;

EID: 0031918460     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02123.x     Document Type: Article

References (18)

1. Goulden V, Layton AM, Cunliffe WJ. Current indications for isotretinoin as a treatment for acne vulgaris. Dermatology 1995; 190: 284-7.
2. Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 1992; 27: 82-7.
3. Lammer EJ, Chen DT, Hoar RM et al. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837-41.
4. Agnish ND, Kochlar DM. Developmental toxicity of retinoids. In: Retinoids in Clinical Practice (Koren G, ed.), New York: Marcel Dekker, 1992; 47-76.
5. Hendrickx AG, Hummler H. Teratogenicity of all-trans retinoic acid during early embryonic development in the cynomolgus monkey (Mucaca fascicularis). Teratology 1992; 45: 65-74.
6. Rosa FW. Teratogenicity of isotretinoin (letter). Lancet 1983; ii: 513.
7. Benke PJ. The isotretinoin teratogen syndrome. JAMA 1984; 251: 3267-9.
8. Hill RM. Isotretinoin teratogenicity (letter). Lancet 1984; i: 1465.
9. Braun JT, Franciosi RA, Mastri AR et al Isotretinoin dysmorphic syndrome. Lancet 1984; i: 506-7.
10. Jahn AF, Ganti K. Major auricular malformations due to Accutane. Laryngoscope 1987; 97: 832-5.
11. Mitchell AA, van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-6.
12. Chan A, Keane RJ, Hanna M, Abbott M. Terminations of pregnancy for exposure to oral retinoids in South Australia, 1985-93. Aust NZ J Obstet Gynaecol 1995; 35: 422-6.
13. Higgens CR, Savulesco J, Wojnarowska F. Attitudes to Roaccutane and contraception. Br J Dermatol 1996; 135 (Suppl. 47): 20 (Abstr.).
14. Stenman UH, Alfthan H. HCG determinations: what does the clinician need and what can the laboratory provide? Proc UK NEQAS Meeting 1994; 1: 94-103.
15. WHO. Collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8.
16. Jick H, Jick SS, Gurewich V et al. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995; 346: 1589-93.
17. Spitzer WO, Lewis MA, Heinemann AJ et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-8.
18. Farmer RDT, Lawrenson RA, Thompson CR et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-8.